Investment Summary

Ampersand Capital Partners Invests In Vernal Biosciences

On June 2, 2022, growth capital firm Ampersand Capital Partners invested in life science company Vernal Biosciences

Investment Highlights
  • This is Ampersand Capital Partners’ 35th transaction in the Life Science sector.
  • This is Ampersand Capital Partners’ 60th transaction in the United States.
  • This is Ampersand Capital Partners’ 1st transaction in Vermont.

Investment Summary
Date 2022-06-02
Target Vernal Biosciences
Sector Life Science
Investor(s) Ampersand Capital Partners
Deal Type Venture

Target

Vernal Biosciences

Colchester, Vermont, United States
Vernal Biosciences provides mRNA and LNP-mRNA manufacturing services to democratize the use of mRNA for all use cases ranging from drug discovery to clinical development across all use cases such as gene editing and regulation, cellular programming, vaccines, mRNA replacement, oncology, autoimmune, and protein degradation. Vernal Biosciences is based in Colchester, Vermont.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Investor(S) 1

Investor

Ampersand Capital Partners

Wellesley, Massachusetts, United States

Investor Investor Investor Investor Investor

Category Growth Capital Firm
Founded 1988
PE ASSETS 2.0B USD
Size Large
Type Sector Focused
DESCRIPTION

Ampersand Capital Partners is a middle-market private equity group that concentrates on growth equity investment opportunities in the healthcare sector. The Firm looks to invest $10 to $100 million in businesses with $10 to $100 million of revenue. Specific areas of interests within healthcare include lab products, specialty diagnostic equipment, pharmaceutical outsourcing, and specialty pharma. Ampersand generally prefers to be the first and sole institutional investor. Ampersand was formed in 1988 and is based in Wellesley, Massachusetts.

DEAL STATS #
Overall 70 of 82
Sector (Life Science) 35 of 42
Type (Venture) 11 of 11
State (Vermont) 1 of 1
Country (United States) 60 of 67
Year (2022) 5 of 10
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2022-04-21 NuvinkaDx

Salem, New Hampshire, United States

NuvinkaDx, a global diagnostics company, brings established expertise in immunodiagnostics and molecular diagnostics. NuvinkaDx is based in Salem, New Hampshire.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2022-06-23 Vantage MedTech

Moonachie, New Jersey, United States

Vantage MedTech is a provider of custom electromechanical and software solutions for the medical device industry. Vantage MedTech was founded in 1998 and is based in Moonachie, New Jersey.

Buy -
Mergr

Product

Company

Legal